Skip to Main Content

Verve Therapeutics said Tuesday its one-time treatment that uses the “base editing” form of CRISPR to remove a cholesterol-associated gene in monkeys has demonstrated durable and significant reductions in LDL “bad” cholesterol for six months.

Based on these new data, Verve intends to advance the treatment, called VERVE-101, into clinical development for people born with heterozygous familial hypercholesterolemia, or HeFH, a genetic heart disease that causes lifelong, high LDL levels

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!